ACT Capital's Contrarian Play: Buying TG Therapeutics at a Moat Discount Amid 30% Skepticism

On February 17, 2026, ACT Capital Management disclosed a new position in TG Therapeutics, acquiring 268,875 shares worth $8,015,164. This move established a significant stake, representing 6.5% of its $123.67 million in reportable U.S. equity assets as of year-end. In a portfolio context, it became the fund's fifth-largest holding.

The setup for this bet is straightforward and contrarian. The stock has been under severe pressure, trading at $28.58 as of Monday and down roughly 30% over the past year. That decline has starkly underperformed the broader market, which gained about 18% in the same period. For a disciplined value investor, this creates a tension: a major allocation to a single stock that has clearly disappointed shareholders over the long term.

ACT's action frames the central question. The fund is essentially betting that the current price, which reflects deep skepticism, has priced in more than the company's underlying business merits. The thesis hinges on a durable competitive moat-TG Therapeutics' commercial-stage pipeline focused on B-cell malignancies and autoimmune diseases-being undervalued against the backdrop of a struggling share price. It's a classic setup where the market's fear of near-term disappointment may be overshadowing the potential for long-term compounding if the company can execute on its growth trajectory.

The Moat: TG Therapeutics' Competitive Position

For a value investor, the core question is whether a company possesses a durable competitive advantage-a "moat"-that can protect its economic profits over time. TG Therapeutics operates in a niche but critical space: developing therapies for B-cell malignancies and autoimmune diseases. This focus targets areas with significant unmet medical need, a classic foundation for a wide moat. The company's business model is that of a commercial-stage biopharmaceutical firm, generating revenue through the sale of proprietary pharmaceutical products, primarily its key drug, BRIUMVI.

The durability of this moat hinges on execution and pipeline depth. The company's recent financials show a clear pivot to a commercial engine. Product sales for BRIUMVI alone reached $606.9 million in 2025, nearly doubling from the prior year. This rapid adoption has driven total annual revenue to about $616.3 million. The drug's success in treating relapsing forms of multiple sclerosis provides a strong, cash-generating foundation. Yet, the stock's 30% decline over the past year suggests the market is skeptical about the sustainability of this growth trajectory, perhaps fearing competition or a plateau. The pipeline offers the next layer of potential moat-building. TG Therapeutics has a portfolio of monoclonal antibodies and targeted small molecules, including umbralisib, which targets specific pathways in B-cell cancers. This diversified pipeline is essential for long-term compounding, as it aims to address the next wave of unmet needs and extend the company's commercial reach beyond its current flagship. The fund's allocation alongside other biotech names like Abivax and Krystal Biotech suggests a strategic bet on innovative drug developers with high-risk, high-reward potential. In this context, ACT Capital is not just buying a current cash flow generator; it is betting on the company's ability to successfully navigate its pipeline and maintain a technological edge in a competitive field.

The bottom line is that the moat appears to be in transition. It is currently anchored by a rapidly growing commercial product, but its future width depends on the successful clinical and commercial execution of its pipeline. The current depressed valuation may reflect the market's uncertainty about this transition. For a patient investor, the thesis is that the underlying business model and pipeline represent a valuable asset that the market has undervalued due to near-term disappointment.

Valuation and the Long-Term Compounding Case

For a value investor, the calculus shifts when a company is not a cash-generating machine but a portfolio of future potential. TG Therapeutics, with its $4.6 billion market capitalization, is not valued on its current earnings, which are substantial, but on the successful clinical and commercial development of its pipeline. The investment thesis here is a pure bet on probability and future monetization. The fund is essentially paying for the option to own a successful drug developer, with the option premium being the depressed share price.

The primary risk in this setup is the need for future capital. As a commercial-stage company with a pipeline, TG Therapeutics will require significant investment to fund clinical trials and commercial expansion. This creates a constant vulnerability to dilution. Each future capital raise, whether through equity or convertible debt, would reduce the ownership stake of existing shareholders. The market's 30% decline over the past year may reflect this very risk-the fear that the company will need to raise money at unfavorable prices to fund its growth, thereby watering down the value of the current equity.

The long-term compounding case, therefore, hinges on two linked probabilities: clinical success and financial discipline. First, the company must successfully navigate its pipeline, turning its monoclonal antibodies and targeted small molecules into approved, best-in-class therapies. Second, it must do so without burning through cash at a rate that forces a dilutive capital raise. The current valuation, which prices in a high degree of skepticism, would need to be justified by a pipeline that not only succeeds but also commands premium commercial terms.

ACT Capital's bet, then, is a classic contrarian play on a high-risk, high-reward asset. It is not a purchase of a business trading below book value, but an investment in a future stream of profits that has yet to be realized. The fund is accepting the volatility of clinical and regulatory outcomes in exchange for the potential of a wide moat that could compound value over a decade. For a patient investor, the key question is whether the current price adequately compensates for the dilution risk and the uncertainty of the pipeline path. The fund's significant allocation suggests it believes the odds favor eventual success.

Catalysts, Risks, and What to Watch

For a value investor, the path from a depressed price to realized value is paved with specific events. The key catalysts for TG Therapeutics are clinical and commercial milestones that will validate or undermine the company's pipeline moat. The most decisive near-term event is the readout of clinical trial data for its key pipeline candidates. Positive results could dramatically re-rate the stock by extending the commercial life of its proprietary assets and justifying the current market cap. Conversely, setbacks would likely deepen the skepticism that has driven the 30% decline.

Beyond the lab, watch for strategic partnerships or acquisition interest. In a market that has undervalued the stock, a major biotech player might see an opportunity to acquire TG's commercial engine and pipeline at a discount. Such a transaction would provide a clear, near-term value realization for shareholders, potentially at a premium to the current price. The company's focus on B-cell malignancies and autoimmune diseases is a niche with consistent M&A activity, making this a plausible, if uncertain, scenario.

The most critical operational risk, however, is the cash runway. The company's rapid commercial expansion and pipeline development require substantial capital. The market's long-term decline likely reflects concerns about future dilution. Investors must monitor the balance sheet for signs of strain. Any indication that the company is burning cash faster than projected would increase the probability of a dilutive financing, which would directly pressure existing shareholders. The fund's bet assumes the company can fund its growth through operations and partnerships, avoiding the need for a capital raise at unfavorable terms.

The bottom line is that the investment thesis is binary in the near term. The stock's fate will be determined by the next major clinical data readout and the company's financial discipline. For a patient investor, the setup offers a chance to own a potentially valuable asset at a steep discount, but it demands a tolerance for the volatility of clinical outcomes and the constant risk of dilution. The watchlist is clear: follow the data, the partnerships, and the cash burn.